Macrogenics takes another shot at a novel immune checkpoint

Macrogenics takes another shot at a novel immune checkpoint

Submitted by admin on April 22, 2021 - 10:49am
Source: 
EP Vantage
News Tags: 
Macrogenics
MGC018
orlotamab
enoblituzumab
prostate cancer
metastatic castration-resistant prostate cancer
Headline: 
Macrogenics takes another shot at a novel immune checkpoint
snippet: 

Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.

Do Not Allow Advertisers to Use My Personal information